AVP and cardiovascular disorder: For other cardiovascular disease such as acute coronary syndromes, the “2020 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation” [41] recommend against the measurement of copeptin for routine risk or prognosis assessment.